BELGRADE, Mont. , July 1, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Robert (Bob) Di Silvio as President of the

BELGRADE, Mont. , June 10, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CFO, John Gandolfo , will present at the 2014 Newport Coast Securities,

Company reports record core recurring biologics revenues of $8.7 million BELGRADE, Mont. --(BUSINESS WIRE)--May 6, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported

BELGRADE, Mont. --(BUSINESS WIRE)--May 1, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Melanie Head as Vice President of Sales. Ms.

BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 28, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended March

BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 23, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and bioactive coatings for medical applications, announced today that positive results utilizing OsteoSelect ® Demineralized

Core recurring Biologics revenues up 20% from prior year First Quarter total revenue in the range of $8.7 million to $8.9 million , an increase of approximately 7% sequentially, and 2% over the same period last year. First Quarter core recurring Biologics revenue in the range of $8.55 million to

BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Jimmy Bornheimer , Vice President of Finance, and

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 20, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and bioactive coatings for medical applications, announces that results utilizing OsteoSponge ® bone graft for foot and ankle

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 19, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported financial results for the fourth quarter and full year ended December 31,